摘要：The agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPS) introduced intellectual property rules into the multilateral
trading system for the first time, with profound consequences for developing
countries. But the high cost of AIDS treatments has injected an ethical element
into the TRIPS debate, posing new problems for the pharmaceuticals
industry.
